Monte Rosa Therapeutics, INC 10-Q quarterly reports

Monte Rosa Therapeutics reported its second-quarter 2026 financial results, highlighting increased research and development expenses and a net loss, while maintaining substantial cash reserves and significant collaboration revenue from ongoing partnerships.

Monte Rosa Therapeutics reported a significant decrease in collaboration revenue and an increase in operating expenses for Q1 2026, leading to a net loss, while also highlighting substantial cash reserves and ongoing strategic partnerships.

Monte Rosa Therapeutics reported a net income of $7.5 million for the nine months ended September 30, 2025, driven by a new $120 million upfront payment from Novartis and progress in its clinical pipeline.

Monte Rosa Therapeutics reports a significant shift to net income in Q2 2025, driven by collaboration revenue, while advancing its molecular glue degrader pipeline.

Monte Rosa Therapeutics reports a net income of $46.9 million for Q1 2025, primarily driven by collaboration revenue from Roche and Novartis.

Monte Rosa Therapeutics reported its Q3 2024 financial results, showcasing progress in clinical trials and a significant collaboration agreement with Novartis.

Monte Rosa Therapeutics reported its second quarter 2024 financial results, highlighting a collaboration revenue of $5.8 million and a net loss of $62.3 million.

Monte Rosa Therapeutics reported a net loss of $31.968 million for the first quarter of 2024, while highlighting advancements in its molecular glue degrader programs and platform technology.